Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
RESEARCH TOOLSreports
Holding CLRB?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.35Last Year’s EPS
-$0.41Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 18, 2024
|% Change Since: -87.37%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call showcased significant progress in clinical trials and financial stability, with promising market opportunities for iopofosine I 131. However, challenges such as the NDA submission delay and increased expenses were acknowledged. The company's extensive pipeline development and strategic collaborations highlight a forward-looking growth strategy, despite regulatory hurdles.Company Guidance
During the Cellectar Biosciences Q3 2024 earnings call, significant guidance was provided regarding the company's strategic trajectory and key metrics. The CLOVER-WaM study yielded compelling outcomes with a major response rate of 56.4%, an overall response rate of 80%, and a clinical benefit rate of 98.2% in heavily pretreated Waldenstrom's macroglobulinemia (WM) patients. These results are set to be presented at the American Society of Hematology's Annual Meeting. The company plans to submit a New Drug Application (NDA) for iopofosine I 131 in the first half of 2025, with anticipated market approval and product launch in the second half of 2025. Financially, Cellectar ended the quarter with $34.3 million in cash and cash equivalents, supported by a warrant strategy potentially raising an additional $73.3 million. Research and development expenses for the quarter were $5.5 million, while general and administrative expenses rose to $7.8 million, primarily due to commercialization efforts. The net loss stood at $14.7 million, compared to $17.5 million in the same period last year.CLOVER-WaM Study Results
The CLOVER-WaM study demonstrated a 56.4% major response rate, 80% overall response rate, and 98.2% clinical benefit rate in the most heavily pretreated WM patient population. The outcomes were selected for an oral presentation at the American Society of Hematology's Annual Meeting.
Positive Financial Position
Cellectar ended the quarter with $34.3 million in cash and cash equivalents, significantly higher than $9.6 million at the end of 2023. The company raised $19.4 million from investor exercises of Tranche B warrants.
Market Opportunity for Iopofosine I 131
Iopofosine I 131 targets a market of approximately 5,700 third-line or greater WM patients in the U.S., with no FDA-approved treatments for those progressing on BTKI therapy.
Pipeline and Research Development
Cellectar is advancing its pipeline of targeted radiotherapies, including a collaboration with City of Hope for iopofosine I 131 in mycosis fungoides and the development of CLR-121225 for solid tumors.
---
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 18, 2024 | $1.86 | $1.77 | -4.84% |
| Aug 13, 2024 | $1.86 | $2.02 | +8.60% |
| May 14, 2024 | $3.06 | $3.18 | +3.92% |
| Mar 27, 2024 | $3.85 | $3.64 | -5.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.35.
---